European guidelines on cardiovascular disease prevention in clinical practice
References (0)
Cited by (103)
Obstructive coronary artery disease diagnostics: machine learning approach for an effective preselection of patients
2021, Cardiovascular and Coronary Artery Imaging: Volume 1Application in nutrition: Cholesterol-lowering activity
2021, Biologically Active Peptides: From Basic Science to Applications for Human HealthProtective effect of Fisetin against angiotensin II-induced apoptosis by activation of IGF-IR-PI3K-Akt signaling in H9c2 cells and spontaneous hypertension rats
2019, PhytomedicineCitation Excerpt :Further, in vivo studies also demonstrated that SHR animals display significantly reduced levels of p-IGF1R, p-PI3K, p-AKT and SHR rats treated with fisetin significantly increased these cell survival proteins when compared to SHR-control (Fig. 5C and D). Cardiovascular disease is the leading cause of death globally and is a growing health concern (De Backer et al., 2003). Traditionally, research and therapy have focused to identify and inhibit the pathological hypertrophy, cardiac dysfunction and heart failure.
Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: Findings from the EUROASPIRE III survey
2013, AtherosclerosisCitation Excerpt :The results of the EUROASPIRE III survey show that despite the clear evidence of the benefits of lipid-lowering treatment in secondary prevention, many coronary patients with dyslipidaemia are still inadequately treated and a significant number of patients on lipid-lowering therapy is still not reaching the treatment goals. Almost half of all coronary patients did not reach the LDL-C goal of ≤2.5 mmol/L and about the same percentage did not reach the total cholesterol goal of ≤4.5 mmol/L according to the Joint European Societies guidelines on cardiovascular disease prevention in everyday clinical practice published in 2003 [11]. It has to be stressed that there were considerable variations between the participating centres from 22 countries involved, in the distribution of serum lipids, the use of lipid-lowering drugs, and the proportion of coronary patients reaching the total cholesterol and LDL-C goals.